No Data
No Data
Insights Into Regeneron Pharmaceuticals's Upcoming Earnings
Regeneron Pharmaceuticals Announces The Upcoming Presentation Of 27 Abstracts, Including Eight Oral Presentations On EYLEA HD Injection 8 MG . Data Will Be Presented at the Association For Research In Vision and Ophthalmology 2025 Annual Meeting May 4...
Regeneron Pharmaceuticals Announces That The European Commission Has Granted Conditional Marketing Approval Of Lynozyfic To Treat Adults With Relapsed And Refractory Multiple Myeloma
Express News | Lynozyfic™ (Linvoseltamab) Approved in the European Union for the Treatment of Relapsed/Refractory Multiple Myeloma
EYLEA HD (Aflibercept) Injection 8 Mg Presentations at ARVO Reinforce Continued Safety and Efficacy and Highlight Early Real-World Outcomes for Patients With Serious Retinal Disease
Notable Healthcare Headlines for the Week: Merck, Roche and Bausch Health in Focus